A phase II, multi center, double-blind, randomized, placebo controlled, dose-escalation, pharmacokinetic and pharmacodynamic study of CK-1827452 in patients with stable heart failure

Trial Profile

A phase II, multi center, double-blind, randomized, placebo controlled, dose-escalation, pharmacokinetic and pharmacodynamic study of CK-1827452 in patients with stable heart failure

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 19 Aug 2011 Results from this trial have been published in The Lancet, according to a Cytokinetics media release.
    • 15 Sep 2009 Results were presented at the 2009 Heart Failure Society of America Annual Meeting in Boston, Massachusetts, according to a Cytokinetics media release.
    • 31 Aug 2009 Results were presented at the European Society of Cardiology Congress 2009, according to a Cytokinetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top